These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30833209)

  • 21. Neointimal Healing Evaluated by Optical Coherence Tomography after Drug-Eluting Absorbable Metal Scaffold Implantation in de novo Native Coronary Lesions: Rationale and Design of the Magmaris-OCT Study.
    Karjalainen P; Paana T; Sia J; Nammas W
    Cardiology; 2017; 137(4):225-230. PubMed ID: 28467998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study).
    Krucoff MW; Rutledge DR; Gruberg L; Jonnavithula L; Katopodis JN; Lombardi W; Mao VW; Sharma SK; Simonton CA; Tamboli HP; Wang J; Wilburn O; Zhao W; Sudhir K; Hermiller JB
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1298-309. PubMed ID: 22192371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiographic performance of a novel sirolimus-coated balloon in native coronary lesions: the FAtebenefratelli SIrolimus COated NATIVES prospective registry.
    Cortese B; Pellegrini D; Latini RA; Di Palma G; Perotto A; Orrego PS
    J Cardiovasc Med (Hagerstown); 2019 Jul; 20(7):471-476. PubMed ID: 30994510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions - Implications from early clinical experience during daily practice.
    Wiebe J; Dörr O; Bauer T; Liebetrau C; Boeder N; Möllmann H; Hamm CW; Nef HM
    Cardiovasc Revasc Med; 2016; 17(5):313-7. PubMed ID: 27085220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second-Generation Drug-Eluting Resorbable Magnesium Scaffold: Review of the Clinical Evidence.
    Ozaki Y; Garcia-Garcia HM; Shlofmitz E; Hideo-Kajita A; Waksman R
    Cardiovasc Revasc Med; 2020 Jan; 21(1):127-136. PubMed ID: 31662277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique.
    Reichart C; Wöhrle J; Markovic S; Rottbauer W; Seeger J
    BMC Cardiovasc Disord; 2019 Jan; 19(1):22. PubMed ID: 30658574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
    Margolis JR
    JACC Cardiovasc Interv; 2009 Apr; 2(4):310-1. PubMed ID: 19463442
    [No Abstract]   [Full Text] [Related]  

  • 30. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R).
    Nef HM; Wiebe J; Kastner J; Mehilli J; Muenzel T; Naber C; Neumann T; Richardt G; Schmermund A; Woehrle J; Zahn R; Riemer T; Achenbach S; Hamm CW
    EuroIntervention; 2017 Dec; 13(11):1311-1318. PubMed ID: 28829745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
    Klauss V; Serruys PW; Pilgrim T; Buszman P; Linke A; Ischinger T; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; van Geuns RJ; van Es GA; Kalesan B; Wenaweser P; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2011 Aug; 4(8):887-95. PubMed ID: 21851904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent.
    Dalos D; Gangl C; Roth C; Krenn L; Scherzer S; Vertesich M; Lang I; Maurer G; Neunteufl T; Berger R; Delle-Karth G
    BMC Cardiovasc Disord; 2016 May; 16():104. PubMed ID: 27225486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One-year clinical outcomes and multislice computed tomography angiographic results following implantation of the NeoVas bioresorbable sirolimus-eluting scaffold in patients with single de novo coronary artery lesions.
    Wang XZ; Zhang YJ; Fu GS; Jing QM; Xu B; Han YL
    Catheter Cardiovasc Interv; 2018 Feb; 91(S1):617-622. PubMed ID: 29392879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry.
    Wlodarczak A; Lanocha M; Jastrzebski A; Pecherzewski M; Szudrowicz M; Jastrzebski W; Nawrot J; Lesiak M
    Catheter Cardiovasc Interv; 2019 Apr; 93(5):E287-E292. PubMed ID: 30537203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of non-compliant balloon postdilatation on magnesium-based bioresorbable vascular scaffolds.
    Blachutzik F; Achenbach S; Tröbs M; Marwan M; Weissner M; Nef H; Schlundt C
    Catheter Cardiovasc Interv; 2019 Feb; 93(2):202-207. PubMed ID: 30196573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
    Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The bioresorbable magnesium scaffold (Magmaris)-State of the art: From basic concept to clinical application.
    Rola P; Włodarczak S; Doroszko A; Lesiak M; Włodarczak A
    Catheter Cardiovasc Interv; 2022 Nov; 100(6):1051-1058. PubMed ID: 36229949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease.
    Diletti R; Ishibashi Y; Felix C; Onuma Y; Nakatani S; van Mieghem NM; Regar E; Valgimigli M; de Jaegere PP; van Ditzhuijzen N; Fam JM; Ligthart JMR; Lenzen MJ; Serruys PW; Zijlstra F; Jan van Geuns R
    Catheter Cardiovasc Interv; 2017 Jul; 90(1):58-69. PubMed ID: 27896897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.